140 related articles for article (PubMed ID: 11531830)
21. Alopecia areata: topical immunotherapy treatment with diphencyprone.
Avgerinou G; Gregoriou S; Rigopoulos D; Stratigos A; Kalogeromitros D; Katsambas A
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):320-3. PubMed ID: 18005118
[TBL] [Abstract][Full Text] [Related]
22. Topical immunotherapy of alopecia areata.
van der Steen PH; Happle R
Dermatol Clin; 1993 Jul; 11(3):619-22. PubMed ID: 8365044
[TBL] [Abstract][Full Text] [Related]
23. In vitro cytokine profile in childhood alopecia areata and the immunomodulatory effects of AS-101.
Shohat M; Mimouni D; Ben-Amitai D; Sredni B; Sredni D; Shohat B; David M
Clin Exp Dermatol; 2005 Jul; 30(4):432-4. PubMed ID: 15953089
[TBL] [Abstract][Full Text] [Related]
24. Pronounced perifollicular lymphocytic infiltrates in alopecia areata are associated with poor treatment response to diphencyprone.
Freyschmidt-Paul P; Hamm H; Happle R; Hoffmann R
Eur J Dermatol; 1999 Mar; 9(2):111-4. PubMed ID: 10066958
[TBL] [Abstract][Full Text] [Related]
25. Five-year experience in the treatment of alopecia areata with DPC.
El-Zawahry BM; Bassiouny DA; Khella A; Zaki NS
J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):264-9. PubMed ID: 19744175
[TBL] [Abstract][Full Text] [Related]
26. Subclinical sensitization with diphenylcyclopropenone is sufficient for the treatment of alopecia areata: Retrospective analysis of 159 cases.
Choe SJ; Lee S; Pi LQ; Keum DI; Lee CH; Kim BJ; Lee WS
J Am Acad Dermatol; 2018 Mar; 78(3):515-521.e4. PubMed ID: 29108907
[TBL] [Abstract][Full Text] [Related]
27. Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata--a large retrospective study on 142 patients with a self-controlled design.
Ohlmeier MC; Traupe H; Luger TA; Böhm M
J Eur Acad Dermatol Venereol; 2012 Apr; 26(4):503-7. PubMed ID: 21569118
[TBL] [Abstract][Full Text] [Related]
28. Decreased in vitro lymphocyte stimulation and reduced sensitivity to IL-2 in patients with alopecia areata.
Orecchia G; Capelli E; Martinetti M; Cuccia Belvedere M; Rabbiosi G
Arch Dermatol Res; 1988; 280 Suppl():S47-50. PubMed ID: 3261574
[TBL] [Abstract][Full Text] [Related]
29. Topical immunotherapy in alopecia areata: anamnestic and clinical criteria of prognostic significance.
Weise K; Kretzschmar L; John SM; Hamm H
Dermatology; 1996; 192(2):129-33. PubMed ID: 8829494
[TBL] [Abstract][Full Text] [Related]
30. Topical immunotherapy in children with alopecia areata.
Orecchia G; Malagoli P
J Invest Dermatol; 1995 May; 104(5 Suppl):35S-36S. PubMed ID: 7738389
[No Abstract] [Full Text] [Related]
31. Possible advantage of imiquimod and diphenylcyclopropenone combined treatment versus diphenylcyclopropenone alone: An observational study of nonresponder patients with alopecia areata.
Wasyłyszyn T; Borowska K
Australas J Dermatol; 2017 Aug; 58(3):219-223. PubMed ID: 27087586
[TBL] [Abstract][Full Text] [Related]
32. Topical immunotherapy in the treatment of chronic severe alopecia areata.
Shapiro J
Dermatol Clin; 1993 Jul; 11(3):611-7. PubMed ID: 8365043
[TBL] [Abstract][Full Text] [Related]
33. Topical immunotherapy in alopecia areata.
Happle R
J Invest Dermatol; 1991 May; 96(5):71S-72S. PubMed ID: 2022878
[No Abstract] [Full Text] [Related]
34. Topical immunomodulation with diphenylcyclopropenone for alopecia areata: the Lebanese experience.
El Khoury J; Abd-el-Baki J; Succariah F; Abbas O; Kibbi AG; Kurban M
Int J Dermatol; 2013 Dec; 52(12):1551-6. PubMed ID: 24134785
[TBL] [Abstract][Full Text] [Related]
35. Home-based contact immunotherapy with diphenylcyclopropenone improves compliance with the recommended follow-up for patients with alopecia areata: A retrospective cohort study.
Kim BJ; Lee S; Lee CH; Lee WS
J Am Acad Dermatol; 2020 May; 82(5):1223-1225. PubMed ID: 31678469
[No Abstract] [Full Text] [Related]
36. Topical immunotherapy with diphenylcyclopropenone-induced vitiligo.
Kutlubay Z; Engin B; Songur A; Serdaroglu S; Tuzun Y
J Cosmet Laser Ther; 2016 Aug; 18(4):245-6. PubMed ID: 26963903
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone.
van der Steen PH; van Baar HM; Happle R; Boezeman JB; Perret CM
J Am Acad Dermatol; 1991 Feb; 24(2 Pt 1):227-30. PubMed ID: 2007667
[TBL] [Abstract][Full Text] [Related]
38. Apoptosis resistance in peripheral blood lymphocytes of alopecia areata patients.
Zöller M; McElwee KJ; Vitacolonna M; Hoffmann R
J Autoimmun; 2004 Nov; 23(3):241-56. PubMed ID: 15501395
[TBL] [Abstract][Full Text] [Related]
39. Pigmented contact dermatitis due to therapeutic sensitizer as complication of contact immunotherapy in alopecia areata.
Inui S; Nakajima T; Toda N; Itami S
J Dermatol; 2010 Oct; 37(10):888-93. PubMed ID: 20860739
[TBL] [Abstract][Full Text] [Related]
40. Serum concentrations of IL-2, IL-6, IL-12 and TNF-α in patients with alopecia areata.
Rossi A; Cantisani C; Carlesimo M; Scarnò M; Scali E; Mari E; Garelli V; Maxia C; Calvieri S
Int J Immunopathol Pharmacol; 2012; 25(3):781-8. PubMed ID: 23058031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
